Labelling Herceptin with a novel oxaliplatin derivative: a computational approach towards the selective drug delivery

Area of Science:

• Oncology
• Biochemistry
• Computational Chemistry

Background:

• Platinum(II)-based drugs cause severe side effects due to non-specific reactions with malignant and normal cells.
• Antibody-drug conjugates offer a strategy for targeted cancer therapy, delivering cytotoxic agents specifically to tumor cells.
• Herceptin (trastuzumab) is a targeted therapy antibody that recognizes breast cancer cells.

Purpose of the Study:

• To investigate the binding stability and mechanism of a novel oxaliplatin derivative conjugated with Herceptin (trastuzumab).
• To provide a theoretical basis for designing improved metallodrugs with enhanced ligand-protein coupling for targeted cancer treatment.

Main Methods:

• Docking simulations to predict initial drug-antibody interactions.
• Molecular dynamics simulations to analyze the dynamic behavior and stability of the drug-antibody complex.
• Quantum calculations to elucidate the electronic interactions and binding mechanism at the atomic level.

Main Results:

• The novel oxaliplatin derivative initially binds non-covalently to Pro40A and Asp167A residues of Herceptin.
• The nitrogen atom of His171B residue facilitates a reversible binding step by coordinating with the platinum center.
• This interaction mechanism reversibly secures the drug within the antibody structure, ensuring targeted delivery.

Conclusions:

• The study elucidates the precise binding mechanism of a novel platinum-based drug conjugated to Herceptin.
• The findings support the rational design of next-generation metallodrugs with improved ligand-protein interactions for enhanced cancer therapy.
• This approach holds promise for developing more effective and less toxic chemotherapy treatments by leveraging antibody-mediated drug delivery.